APR Applied Pharma Research, Receives Notice Of Allowance from USPTO for Ready To Use Diclofenac Stick Packs to treat Migraine
Relief Therapeutics Holding, on Monday, announced that its subsidiary, APR Applied Pharma Research, has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for Patent Application for Ready to Use Diclofenac Packs. Diclofenac potassium is an off-patent, potent non-steroidal anti-inflammatory drug (NSAID) widely used therapeutically for inflammatory conditions and pain management.
“The receipt of this Notice of Allowance from the USPTO is another confirmation of our drug development and reformulation expertise. The new, user-friendly, ready to use, liquid portable stick packs to deliver CAMBIA should improve patient compliance. We look forward to continue to identify, develop and commercialize innovative therapies for patients with niche and rare diseases.”Paolo Galfetti, Chief Executive Officer of APR and President of Relief Europe
By applying the patented dynamic buffering technology (DBT), APR developed the first NSAID ever approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute migraine attacks in adults. The drug has been currently marketed as CAMBIA by Assertio Therapeutics in the U.S. and Miravo Healthcare in Canada.
DBT and CAMBIA are currently protected by a family of four patents listed in the FDA Orange Book which are all expiring in 2026. CAMBIA is currently available in the form of a dry powder packed into a single-dose sachet to be poured and dissolved in water before administration.